Once these most recent quarterly results are finalized, they will be run through TheStreet.com Ratings' model and our ratings will be adjusted accordingly. To keep up to date on all of our ratings, visit TheStreet.com Ratings Screener. On March 5, 2009, SXC Health Solutions ( SXCI) reported a 31.1% year-over-year increase in its Q4 FY08 earnings, driven by revenue from the acquisition of National Medical Health Card Systems (NMHC). Net income rose to $4.95 million or $0.20 per share from $3.78 million or $0.18 per share in Q4 FY07. Moreover, non-GAAP earnings were $0.28 per share, which beat the most recent consensus estimate of $0.13 per share. SXCI's revenue surged multi-fold to $292.77 million from $23.55 million. Pharmacy Benefit Manager revenue was $269.80 million, reflecting the addition of 8 months of NMHC's business. Health Care Information Technology (HCIT) revenue inched down 2.5% to $22.96 million. Recurring revenue accounted for 81.3% of HCIT revenue, compared to 79.7% in Q4 FY07. Within the segment, revenue from transaction processing rose 3.1% to $14.61 million, while maintenance revenue dipped 2.1% to $4.06 million. Professional services sales plunged 30.8% to $2.79 million, and system sales increased 25.0% to $1.51 million. SXC Health recently bought privately held formulary agent Zynchros. SXCI won a three-year contract to provide its resident care management services to PharMerica Corp. Additionally, the company's informedRx PBM unit entered into a three-year contract to offer services to the 110,000 member UFCW & Employers Benefit Trust. This contract is expected to generate $80.00 million revenue annually. PBM division also signed a 5-year agreement with the Health Plan of San Mateo, valued at $50.00 million per year. During FY08, net profit spiked 15.0% to $15.11 million or $0.65 per share from $13.15 million or $0.61 per share in FY07. Annual revenue soared more than nine-fold to $862.94 million from $93.17 million. Looking ahead to FY09, SXCI expects revenue to range between $1.20 billion and $1.30 billion and EPS of $0.77 to $0.85. Non-GAAP EPS is anticipated to range between $0.99 per share and $1.08 per share.